Showing results (141-150 of 250) with videos related to
Sort By:
Pageof 25
British Journal of Haematology|February 28, 2014
LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphomaChen Lossos, Soley Bayraktar, Elizabeth Weinzierl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS TumorsMrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.JCO Oncology Practice|June 25, 2024
Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS LymphomaLauren R Schaff, Dean Carlow, Ryan Schofield, et al.Journal of Neuro-Oncology|June 29, 2011
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.Neuro-Oncology|August 12, 2011
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2003
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysisLauren E Abrey, Craig H Moskowitz, Warren P Mason, et al.Neuro-Oncology|March 5, 2010
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Fabio M Iwamoto, Kathleen R Lamborn, H Ian Robins, et al.Annals of Neurology|March 11, 2011
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger, Fabio M Iwamoto, Sasan Karimi, et al.Plos One|January 6, 2016
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung CancersBob T Li, Emil Lou, Meier Hsu, et al.Annals of Clinical and Translational Neurology|April 16, 2020
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastomaThomas J Kaley, Katherine S Panageas, Elena I Pentsova, et al.Pageof 25